Log in

ASX:AFPAft Pharmaceuticals Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
AFT Pharmaceuticals Limited develops, licenses, and sells pharmaceutical products in New Zealand, Australia, Southeast Asia, and internationally. The company offers approximately 130 prescription and non-prescription products for use in the areas of allergy, eye care, first aid, fungal, pain management, and skin care, as well as supplements. It is also involved in the distribution of pharmaceuticals. The company was founded in 1997 and is headquartered in Auckland, New Zealand.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers—Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone64 9 488 0232

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive AFP News and Ratings via Email

Sign-up to receive the latest news and ratings for AFP and its competitors with MarketBeat's FREE daily newsletter.

Aft Pharmaceuticals (ASX:AFP) Frequently Asked Questions

Has Aft Pharmaceuticals been receiving favorable news coverage?

News articles about AFP stock have been trending negative recently, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aft Pharmaceuticals earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near term. View the latest news about Aft Pharmaceuticals.

Who are some of Aft Pharmaceuticals' key competitors?

Who are Aft Pharmaceuticals' key executives?

Aft Pharmaceuticals' management team includes the following people:
  • Dr. Hartley Atkinson, Founder, CEO, MD & Exec. Director
  • Ms. Marree Atkinson, Chief of Staff & Exec. Director
  • Mr. Malcolm Tubby B.A., BA(Hon's), ICAEW, ICANZ, CFO & Company Sec.
  • Mr. Murray Keith, Group Marketing Mang.
  • Ms. Ioana Stanescu, Head of Drug Devel.

What is Aft Pharmaceuticals' stock symbol?

Aft Pharmaceuticals trades on the ASX under the ticker symbol "AFP."

How big of a company is Aft Pharmaceuticals?

Aft Pharmaceuticals has a market capitalization of $0.00. Aft Pharmaceuticals employs 86 workers across the globe.

What is Aft Pharmaceuticals' official website?

The official website for Aft Pharmaceuticals is www.aftpharm.com.

How can I contact Aft Pharmaceuticals?

The company can be reached via phone at 64 9 488 0232.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.